Trial · NCT00606905

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

NCT00606905, Not applicable, Completed, University of Chicago; results first posted 2010-08-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage. Trials, record NCT00606905. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00606905

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
NCT number: NCT00606905
Status: Completed
Phases: Not applicable
Enrollment: 82 participants, actual
Lead sponsor: University of Chicago
Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline
First posted: 2008-02-05
Last updated: 2012-10-08
Results first posted: 2010-08-30

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Successful Pregnancies Defined as an Ongoing Pregnancy Over 20 Weeks Gestation, Per Number of Index Pregnancies	20 weeks gestation

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Successful Pregnancies Defined as an Ongoing Pregnancy Over 20 Weeks Gestation, Per Number of Index Pregnancies	20 weeks gestation	47 women who achieved an index pregnancy, defined as the first pregnancy in the study, unless it resulted in a noneuploid miscarriage, ectopic, molar pregnancy or genetic termination, were analyzed.	Successful pregnancies	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Successful Pregnancies Defined as an Ongoing Pregnancy Over 20 Weeks Gestation, Per Number of Index Pregnancies	IVIG		16		Successful pregnancies
Number of Successful Pregnancies Defined as an Ongoing Pregnancy Over 20 Weeks Gestation, Per Number of Index Pregnancies	Normal Saline		15		Successful pregnancies

Source ClinicalTrials.gov

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IVIG	38
Overall Study	STARTED	Normal Saline	39
Overall Study	Pregnancy	IVIG	29
Overall Study	Pregnancy	Normal Saline	33
Overall Study	COMPLETED	IVIG	23
Overall Study	COMPLETED	Normal Saline	24
Overall Study	NOT COMPLETED	IVIG	15
Overall Study	NOT COMPLETED	Normal Saline	15

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	myalgia, headaches, nausea, fever or chills	General disorders	IVIG	4	23	5
other	myalgia, headaches, nausea, fever or chills	General disorders	Normal Saline	0	24	0
other	shortness of breath	Respiratory, thoracic and mediastinal disorders	IVIG	1	23	1
other	shortness of breath	Respiratory, thoracic and mediastinal disorders	Normal Saline	0	24	0
other	gastrointestinal symptoms	Gastrointestinal disorders	IVIG	0	23	0
other	gastrointestinal symptoms	Gastrointestinal disorders	Normal Saline	2	24	2
other	rash	Skin and subcutaneous tissue disorders	IVIG	3	23	3
other	rash	Skin and subcutaneous tissue disorders	Normal Saline	0	24	0
other	headache	General disorders	IVIG	1	23	1
other	headache	General disorders	Normal Saline	0	24	0

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IVIG
Total, all-cause mortality	Normal Saline
Total, other adverse events	IVIG	9	23
Total, other adverse events	Normal Saline	2	24
Total, serious adverse events	IVIG	0	23
Total, serious adverse events	Normal Saline	0	24

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20634190	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
IVIG vs Normal Saline: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00606905

GET https://conductscience.org/api/trials/v1/NCT00606905/registered

API reference For AI assistants